Cogent Biosciences, Inc. (COGT)

Cogent Biosciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	215.8	53.23	141.14	220.94	243.45	38.68
Short-Term Investments	219.94	212.48	119.39	0	0	0
Cash & Cash Equivalents	435.74	265.71	260.53	220.94	243.45	38.68
Cash Growth	96.71%	1.99%	17.92%	-9.24%	529.40%	-51.56%
Receivables	0	0	0	0	0	2
Other Current Assets	6.16	5.06	4.44	1.69	1.47	-0.09
Total Current Assets	441.9	270.77	264.97	222.63	244.91	40.59
Property, Plant & Equipment	29.35	30.34	31.1	4.48	4.75	7.15
Long-Term Investments	0	7.46	0	0	0	0
Other Long-Term Assets	4.86	4.86	4.75	4.98	1.26	1.68
Total Long-Term Assets	34.21	42.67	35.84	9.46	6	8.83
Total Assets	476.11	313.44	300.81	232.09	250.92	49.42
Accounts Payable	15.57	10.66	5.84	3.48	0.73	3.18
Deferred Revenue	0	0	0	0	0	1.32
Current Debt	1.43	1.39	1.42	2.32	2.05	1.62
Other Current Liabilities	19.69	26.13	19.58	11.27	10.31	7.13
Total Current Liabilities	36.69	38.17	26.85	17.08	13.09	13.25
Long-Term Debt	17.09	17.47	18.23	0.83	3.16	4.41
Total Long-Term Liabilities	17.09	17.47	18.23	0.83	3.16	4.41
Total Liabilities	53.78	55.64	45.08	17.91	16.25	17.66
Total Debt	18.52	18.85	19.65	3.16	5.21	6.03
Debt Growth	-4.82%	-4.05%	522.79%	-39.41%	-13.68%	-
Retained Earnings	-661.97	-603.62	-411.21	-270.97	-198.7	-123.89
Comprehensive Income	-0.04	0.25	-0.1	0	0	0
Shareholders' Equity	422.33	257.8	255.74	214.18	234.67	31.76
Net Cash / Debt	417.22	246.86	240.88	217.78	238.24	32.65
Net Cash / Debt Growth	106.48%	2.48%	10.61%	-8.59%	629.74%	-59.11%
Net Cash Per Share	4.40	3.10	4.10	5.62	21.50	4.28
Working Capital	405.22	232.6	238.12	205.56	231.82	27.34
Book Value Per Share	4.46	3.24	4.35	5.53	21.18	4.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).